Merck announced the expansion of its end-to-end biodevelopment centers, including the opening of two new process development centers in the Shanghai and Boston metropolitan areas. Each will provide a full range of process development capabilities and services, including cell line development services, both upstream and downstream process development, as well as non-GMP clinical production. The operation address the increasing customer demand for bioprocessing products, manufacturing capabilities.

SHARE

LEAVE A REPLY

Please enter your comment!
Please enter your name here